Stockreport

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]

Relay Therapeutics, Inc.  (RLAY) 
PDF Plan to initiate 2L pivotal trial of RLY-2608 + fulvestrant in 2025 Approximately $840 million in cash, cash equivalents and investments at end of Q3 2024, expected t [Read more]